ALB and non-small cell lung carcinoma: Overall, a third- or later-line regimen of camrelizumab plus albumin-bound paclitaxel greatly prolonged PFS and OS in patients with advanced NSCLC, suggesting that the regimen in our study has a better trend for survival for advanced NSCLC patients compared to camrelizumab monotherapy.